Clinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: A systematic review and meta-analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yan, Lin ^a   Zou, Lei ^b   Zhao, Wenhua ^c   Wang, Yansen ^a   Liu, Bo ^c   Yao, Hongliang ^d   Yu, Haihua ^c  

^a Department of oncology Shandong Jiaotong Hospital ^*  (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c SHANDONG UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

EXON; GASTROINTESTINAL STROMAL TUMORS; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; MORTALITY; MUTATION; ODDS RATIO; PROGNOSIS; RISK;

EXONS; GASTROINTESTINAL STROMAL TUMORS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; ODDS RATIO; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RISK;

EID: 84941556301     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13718     Document Type: Article

References (45)

1. Goettsch, W. G., et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 41, 2868-2872, doi: S0959-8049(05)00797-5 (2005
2. Nilsson, B., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-A population-based study in western Sweden. Cancer 103, 821-829, doi: 10.1002/cncr.20862 (2005
3. Joensuu, H. Gastrointestinal stromal tumor (GIST). Ann Oncol 17 Suppl 10, x280-286, doi: 17/suppl-10/x280 (2006
4. Hirota, S., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580 (1998
5. Corless, C. L. Gastrointestinal stromal tumors: what do we know now?. Mod Pathol 27 Suppl 1, S1-16, doi: 10.1038/modpathol.2013.173 modpathol2013173 (2014
6. Wozniak, A., et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol 23, 353-360, doi: 10.1093/annonc/mdr127 mdr127 (2012
7. Chabot, B., Stephenson, D. A., Chapman, V. M., Besmer, P. & Bernstein, A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335, 88-89, doi: 10.1038/335088a0 (1988
8. Huizinga, J. D., et al. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373, 347-349, doi: 10.1038/373347a0 (1995
9. Corless, C. L., Barnett, C. M. & Heinrich, M. C. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 11, 865-878, doi: 10.1038/nrc3143 nrc3143 (2011
10. Lasota, J. & Miettinen, M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53, 245-266, doi: 10.1111/j.1365-2559.2008.02977.x HIS2977 (2008
11. Miettinen, M. & Lasota, J. Gastrointestinal stromal tumors. Gastroenterol Clin North Am 42, 399-415, doi: 10.1016/j. gtc.2013.01.001 S0889-8553(13)00019-8 (2013
12. Emile, J. F., et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2, 597-605, doi: S1542356504002435 (2004
13. Emile, J. F., Tabone-Eglinger, S., Theou-Anton, N. & Lemoine, A. Prognostic value of KIT exon 11 deletions in GISTs. Gastroenterology 131, 976-977, doi: S0016-5085(06)01686-6 (2006
14. Dematteo, R. P., et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112, 608-615, doi: 10.1002/cncr.23199 (2008
15. Heinrich, M. C., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708-710, doi: 10.1126/science.1079666 1079666 (2003
16. Miettinen, M. & Lasota, J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130, 1466-1478, doi: RA-5-1116 (2006
17. Rammohan, A., et al. A gist of gastrointestinal stromal tumors: A review. World J Gastrointest Oncol 5, 102-112, doi: 10.4251/wjgo.v5.i6.102 (2013
18. Chen, P., Zong, L., Zhao, W. & Shi, L. Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-Analysis. World J Gastroenterol 16, 4227-4232 (2010
19. Zhi, X., Zhou, X., Wang, W. & Xu, Z. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-Analysis. PLoS One 8, e79275, doi: 10.1371/journal.pone.0079275 PONE-D-13-25609 (2013
20. Wardelmann, E., et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106, 887-895, doi: 10.1002/ijc.11323 (2003
21. Gao, J., Dang, Y., Sun, N., Li, J. & Shen, L. C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients. Med Oncol 29, 3039-3045, doi: 10.1007/s12032-012-0308-7 (2012
22. Bachet, J. B., et al. Prognosis and predictive value of KIT exon 11 deletion in GISTs. Br J Cancer 101, 7-11, doi: 10.1038/sj.bjc.6605117 6605117 (2009
23. Hanks, S. K., Quinn, A. M. & Hunter, T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241, 42-52 (1988
24. Duensing, A., et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23, 3999-4006, doi: 10.1038/sj.onc.1207525 1207525 (2004
25. Rossi, F., et al. Oncogenic and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A 103, 12843-12848, doi: 0511076103 (2006
26. Rubin, B. P., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61, 8118-8121 (2001
27. Taniguchi, M., et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59, 4297-4300 (1999
28. Garces-Albir, M., et al. Results on prognostic value of mutations in localized gastrointestinal stromal tumors (GIST) in one single center. Rev Esp Enferm Dig 104, 405-410 (2012
29. Casali, P G., Jost, L., Reichardt, P., Schlemmer, M. & Blay, J. Y. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl 4, 64-67, doi: 10.1093/annonc/mdp131 mdp131 (2009
30. Zhao, W. Y., Cao, H., Zhang, Y., Shen, Z. Y. & Wu, Z. Y. [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-Analysis]. Zhonghua Wai Ke Za Zhi 47, 857-862 (2009
31. Ma, Y. Y., et al. Involvement of c-KIT mutation in the development of gastrointestinal stromal tumors through proliferation promotion and apoptosis inhibition. Onco Targets Ther 7, 637-643, doi: 10.2147/OTT.S60458 ott-7-637 (2014
32. Origone, P., et al. Molecular characterization of an Italian series of sporadic GISTs. Gastric Cancer 16, 596-601, doi: 10.1007/s10120-012-0213-y (2013
33. Lv, A., et al. SKP2 high expression, KIT exon 11 deletions, and gastrointestinal bleeding as predictors of poor prognosis in primary gastrointestinal stromal tumors. PLoS One 8, e62951, doi: 10.1371/journal.pone.0062951 PONE-D-13-03908 (2013
34. Kunstlinger, H., et al. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing. Am J Surg Pathol 37, 1648-1659, doi: 10.1097/PAS.0b013e3182986b88 (2013
35. Gao, J., et al. of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors. Med Oncol 30, 522, doi: 10.1007/s12032-013-0522-y (2011
36. Soreide, K., et al. Tyrosine-kinase mutations in c-KIT and PDGFR-Alpha genes of imatinib naive adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-Term outcome. Clin Transl Oncol 14, 619-629, doi: 10.1007/s12094-012-0851-x (2012
37. Kang, H. J., et al. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Acta Oncol 51, 528-536, doi: 10.3109/0284186X.2011.636753 (2012
38. Daniels, M., et al. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett 312, 43-54, doi: 10.1016/j.canlet.2011.07.029 S0304-3835(11)00454-X (2011
39. Kontogianni-Katsarou, K., et al. KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential. World J Gastroenterol 14, 1891-1897 (2008
40. Tzen, C. Y., Wang, M. N. & Mau, B. L. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors. Eur J Surg Oncol 34, 563-568, doi: S0748-7983(07)00180-1 (2008
41. Imamura, M., et al. Prognostic significance of angiogenesis in gastrointestinal stromal tumor. Mod Pathol 20, 529-537, doi: 3800767 (2007
42. Debiec-Rychter, M., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42, 1093-1103, doi: S0959-8049(06)00175-4 (2006
43. Yeh, C. N., et al. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Ann Surg Oncol 14, 1123-1128, doi: 10.1245/s10434-006-9288-1 (2007
44. Cho, S., et al. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach. Int J Oncol 28, 1361-1367 (2006
45. Martin, J., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23, 6190-6198, doi: 23/25/6190 (2005